# A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

> **NCT05733546** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **COMPASS Pathways** · enrollment: 102 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Psilocybin

## Key facts

- **NCT ID:** NCT05733546
- **Lead sponsor:** COMPASS Pathways
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-30
- **Primary completion:** 2025-09
- **Final completion:** 2025-09
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05733546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05733546, "A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05733546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*